Combination of Thrombolysis and Glycoprotein IIb/IIIa Inhibition in Chronic Peripheral Thrombosis: A Case Report
Journal Title: International Journal of Radiology and Radiation Oncology - Year 2017, Vol 3, Issue 1
Abstract
Currently, many interventionalists employ either tissue plasminogen activator (alteplase, Genentech, San Francisco, CA), or recombinant plasminogen activator (reteplase, Chiesi USA, Inc., Cary, NC), for peripheral thrombolysis. Further, combination therapy utilizing a thrombolytic agent and a glycoprotein IIb/IIIa receptor antagonist has been proposed as a way to overcome the limitations of thrombolytic therapy alone by reducing the duration of infusion, preventing rethrombosis, and improving the efficacy of thrombolysis. The following report discusses a patient with stenoses in the distal right posterior tibial artery. The patient underwent percutaneous transluminal angioplasty along with tissue plasminogen activator infusion therapy. Initially, the tissue plasminogen activator infusion reduced pain. However, an embolic occlusion to the distal right lateral plantar artery led to recurrence of pain. Due to failure of thrombolytic monotherapy using tissue plasminogen activator, a combined treatment of eptifibatide (Integrilin, Cor Therapeutics and Schering-Plough) and tissue plasminogen activator infused intra-arterially was initiated. In this report, the successful clinical use of combination therapy has been demonstrated after failed intra-arterial tissue plasminogen activator infusion monotherapy. The use of purely intra-pedal intra-arterial eptifibatide is novel and should be studied in randomized trials to establish efficacy. Furthermore, we have shown that failure of monotherapy to treat occlusions can be recovered through the use of combination therapy.
Authors and Affiliations
Syed Mubin I, Gallagher Ryan, Hussain Zeshan, Shaikh Azim, Cain Philip J, Morar Kamal, Guehl Allen, Erdelyi Ronald
Keywords
Related Articles
- EP ID EP541303
- DOI 10.17352/ijrro.000020
- Views 70
- Downloads 0
Where We are Standing in the Choice of Most Effective Radiological Imaging for Patient’s Benefits?
Today the radiologic investigations are the indispensable diagnostic tools in medical care especially in emergency, oncology and pediatry departments. The imaging has the benefits for the patients follow-up as well as th...
PSMA Accumulation in Benign Pleural Thickening
Prostate-specific membrane antigen (PSMA) is a specific type II membrane glycoprotein. We present the case of a 72-year-old man with newly diagnosed prostate cancer who had a 68Ga-PSMA PET/CT scan for staging. 68Ga-PSMA...
Adenoid Cystic Carcinoma of the Maxilla, CT Follow-Up: A Case Report
Background: Intraoral adenoid cystic carcinoma is an uncommon pathology with a variable clinical course, it develops as a slow growing swelling characterized by wide local infiltration. Most patients are in their fourth...
Volumetric Modulated Arc Therapy versus Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer: A Systematic Literature Review
Aim: provide evidence concerning advantages of volumetric modulated arc therapy over intensity modulated radiation therapy. Background: external beam radiation therapy is a major treatment modality of prostate cancer; es...
Sclerosing Angiomatoid Nodular Transformation of the Spleen (SANT): CT and MR Imaging Features of Five Cases with Pathological Correlation
Objective: To describe imaging features of sclerosing angiomatoid nodular transformation (SANT) with pathologic correlation. Methods: Imaging findings of five cases of SANT were retrospectively analyzed and compared with...